Novel blood test shows promising accuracy for detection of early-stage pancreatic cancer
A next-generation biomarker-based blood test demonstrated 98% specificity and 75% sensitivity in detecting stage I and II pancreatic ductal adenocarcinoma, according to a press release from the manufacturer.The test, which achieved both primary and secondary endpoints during a model-development study, is more accurate than CA19-9, the biomarker typically used to detect pancreatic cancer,